Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: A retrospective analysis of clinical practice and outcomes

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Bianchi, Antonio ^a   Valentini, Ferdinando ^b   Iuorio, Raffaella ^c   Poggi, Maurizio ^d   Baldelli, Roberto ^e   Passeri, Marina ^f   Giampietro, Antonella ^a   Tartaglione, Linda ^a   Chiloiro, Sabrina ^a   Appetecchia, Marialuisa ^e   Gargiulo, Patrizia ^c   Fabbri, Andrea ^f   Toscano, Vincenzo ^d   Pontecorvi, Alfredo ^a   De Marinis, Laura ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; GROWTH HORMONE SECRETING ADENOMA; HUMAN; ITALY; LIVER TOXICITY; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879107985     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-40     Document Type: Article

References (44)

1. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Holdaway IM, Bolland MJ, Gamble GD, Eur J Endocrinol 2008 159 2 89 95 10.1530/EJE-08-0267 18524797
2. Predictors of morbidity and mortality in acromegaly, an Italian survey. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, Demenis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M, Eur J Endocrinol 2012 167 2 189 198 22596288
3. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Mazziotti G, Giustina A, Pituitary 2010 13 1 60 67 10.1007/s11102-009-0169-z 19189218
4. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S, PLoS One 2012 7 5 36411 10.1371/journal.pone.0036411 22574156
5. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, J Clin Endocrinol Metabol 2009 94 5 1509 1517 10.1210/jc.2008-2421
6. SOMAVERT (pegvisomant) EPAR, Available at this URL: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000409/ WC500054622.pdf (last accessed 15 june 2013)
7. SOMAVERT, Prescribing Information New York. NY: Pfizer 2010
8. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ, N Engl J Med 2000 342 16 1171 1177 10.1056/NEJM200004203421604 10770982
9. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO, Lancet 2001 24 358(9295) 1754 1759
10. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant Investigators, Eur J Endocrinol 2007 156 1 75 82 10.1530/eje.1.02312 17218728
11. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M, J Clin Endocrinol Metabol 2012 97 5 1589 1597 10.1210/jc.2011-2508
12. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ, Lancet 2005 13 365(9471) 1644 1646
13. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ Hagen C, Ørskov H, J Clin Endocrinol Metabol 2005 90 10 5627 5631 10.1210/jc.2005-0531
14. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ, J Clin Endocrinol Metabol 2007 92 12 4598 4601 10.1210/jc.2007-1234
15. Current management practices for acromegaly: an international survey. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S, Pituitary 2011 14 2 125 133 10.1007/s11102-010-0269-9 21063787
16. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ, Clinical Endocrinology (Oxf) 2009 71 4 549 557 10.1111/j.1365-2265.2009.03620.x
17. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ, Eur J Endocrinol 2009 160 4 529 533 19141604
18. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A, Pituitary 2007 10 3 227 232 10.1007/s11102-007-0037-7 17484056
19. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ, Investigators of German Pegvisomant Observational Study, Eur J Endocrinol 2009 161 1 27 35 10.1530/EJE-08-0910 19411302
20. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. Buhk JH, Jung S, Psychogios MN, Göricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Brückmann H, Dörfler A, Jordan M, Buchfelder M, Knauth M, J Clin Endocrinol Metabol 2010 95 2 552 558 10.1210/jc.2009-1239
21. Resistance to somatostatin analogs in acromegaly. Colao A, Auriemma RS, Lombardi G, Pivonello R, Endocrine Review 2011 32 2 247 271 10.1210/er.2010-0002
22. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. Boquete HR, Sobrado PG, Fideleff HL, Sequera AM, Giaccio AV, Suá rez MG, Ruibal GF, Miras M, J Clin Endocrinol Metabol 2003 88 4702 4708 10.1210/jc.2003-030412
23. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P, Eur J Endocrinol 2011 164 3 325 333 10.1530/EJE-10-0867 21148630
24. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, De Marinis L, Martini C, Bogazzi F, Cannavò S, Colao A, Ferone D, Arnaldi G, Pigliaru F, Peri A, Angeletti G, Jaffrain-Rea ML, Lania AG, Spada A, J Clin Endocrinol Metabol 2012 97 2 165 E172 10.1210/jc.2011-1769
25. Features at diagnosis of 324 patients with acromegaly did not change from, to 2006: acromegaly remains under recognized and under-diagnosed. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU, Clin Endocr (Oxf) 2010 1981 72 2 203 208
26. Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Roemmler J, Gutt B, Fischer R, Vay S, Wiesmeth A, Bidlingmaier M, Schopohl J, Angstwurm M, Sleep Breath 2012 16 4 1247 1253 10.1007/s11325-011- 0641-7 22241151
27. German Pegvisomant Observational Study. The German ACROSTUDY: past and present. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ, Eur J Endocrinol 2009 161 1 3 S10 19684061
28. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Neggers SJ, van der Lely AJ, Growth Horm IGF-I Res 2011 21 3 129 133 10.1016/j.ghir.2011.03.004
29. ACROSTUDY: the first 5 years. Trainer PJ, Eur J Endocrinol 2009 161 1 19 S24 19684052
30. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Parkinson C, Burman P, Messig M, Trainer PJ, J Clin Endocrinol Metabol 2007 92 190 195
31. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L, Pituitary 2009 12 3 196 199 10.1007/s11102-008-0157-8 19089622
32. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. Bernabeu I, Alvarez-Escolá C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M, J Clin Endocrinol Metabol 2010 95 1 222 229 10.1210/jc.2009-1630
33. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ, Endocr Rev 2002 23 5 623 646 10.1210/er.2001-0022 12372843
34. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ, J Clin Endocrinol Metabol 2001 86 7 3304 3310 10.1210/jc.86.7.3304
35. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Roelfsema F, Biermasz NR, Pereira AM, Romijn J, Int J Nanomedicine 2006 1 4 385 398 10.2147/nano.2006.1.4.385 17722273
36. Growth hormone excess promotes breast cancer chemoresistance. Zatelli MC, Minoia M, Molè D, Cason V, Tagliati F, Margutti A, Bondanelli M, Ambrosio MR, degli Uberti E, J Clin Endocrinol Metabol 2009 94 10 3931 3938 10.1210/jc.2009-1026
37. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. Minoia M, Gentilin E, Molè D, Rossi M, Filieri C, Tagliati F, Baroni A, Ambrosio MR, degli Uberti E, Zatelli MC, J Clin Endocrinol Metabol 2012 97 6 907 E916 10.1210/jc.2011-3340
38. Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. Asa SL, Coschigano KT, Bellush L, Kopchick JJ, Ezzat S, Am J Pathol 2000 156 3 1009 1015 10.1016/S0002-9440(10)64968-1 10702416
39. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S, Cancer Res 2007 67 15 7505 7511 10.1158/0008-5472.CAN-07-0219 17671221
40. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF, J Clin Endocrinol Metabol 1999 84 6 2098 2103 10.1210/jc.84.6.2098
41. A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans. Veldhuis JD, Bidlingmaier M, Bailey J, Erickson D, Sandroni P, J Clin Endocrinol Metabol 2010 95 8 3844 3847 10.1210/jc.2010-0538
42. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Marazuela M, Lucas T, Alvarez-Escolá C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I, Eur J Endocrinol 2009 160 4 535 542 19147599
43. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ, Clin Endocrinol (Oxf) 2009 71 1 86 91 10.1111/j.1365-2265.2008.03469.x
44. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escolá C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castaño JP, Bernabeu I, J Clin Endocrinol Metabol 2011 96 2 251 E259 10.1210/jc.2010-1742